Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Hematological Diseases, Hospital Clínic Universitari, Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Bone Marrow Transplant. 2024 Sep;59(9):1209-1214. doi: 10.1038/s41409-024-02360-w. Epub 2024 Jul 3.
Extracorporeal photopheresis (ECP) is a therapy that combines the collection of mononuclear cells by apheresis, the addition of a photosensitizer (8-methoxisoralen), the illumination of the product with ultraviolet A light, and the immediate infusion of the product to the patient. Initially developed and approved to treat T-cell cutaneous lymphomas, soon started to be used to treat graft versus host disease (GvHD) developed after allogeneic hematopoietic-cell transplantation. The high response rate of ECP in skin, ocular, oral, pulmonary, and liver forms of chronic GvHD, the steroid-sparing effect, and the improved overall survival of treated patients, made ECP one of the second-line treatments used to treat steroid-resistant acute and chronic GVHD. Recently, the development of new drugs for treating GVHD has changed the position of ECP in the therapy of GVHD and has started to be used in combination with drugs for increasing the response rate to the treatment in severe or resistant forms of acute and chronic GVHD. ECP remains an essential therapeutic resource in the management of patients with refractory acute and chronic GVHD.
体外光分离术（ECP）是一种将单核细胞通过血浆分离术收集，添加光敏剂（8-甲氧基补骨脂素），用紫外线 A 光照射产物，并立即将产物输注给患者的疗法。该疗法最初被开发并批准用于治疗 T 细胞皮肤淋巴瘤，随后开始用于治疗异基因造血细胞移植后发生的移植物抗宿主病（GvHD）。ECP 在慢性 GvHD 的皮肤、眼部、口腔、肺部和肝脏形式中具有较高的反应率、类固醇节省效应以及改善治疗患者的总体生存率，使其成为治疗类固醇耐药性急性和慢性 GVHD 的二线治疗方法之一。最近，治疗 GVHD 的新药的发展改变了 ECP 在 GVHD 治疗中的地位，并开始与药物联合使用，以提高严重或耐药性急性和慢性 GVHD 形式的治疗反应率。ECP 仍然是管理难治性急性和慢性 GVHD 患者的重要治疗资源。
Zotero 插件